What the system-level research shows

Several published trials involve these products, funded by unrestricted Isagenix grants with company employees or advisers among the authors. They test a whole protocol — protein pacing with calorie restriction or intermittent fasting — not a single shake. In one head-to-head over eight weeks the protein-pacing group lost more weight and more visceral fat than a heart-healthy comparison diet, and reported lower desire to eat. In a 52-week follow-up the control group trended back toward baseline on most markers despite a lower average calorie intake. Those are findings about a programme. They are not evidence that this one product, bought on its own, produces that result, and this site will not present them that way.

The trials, named. Intermittent fasting combined with calorie restriction is effective for weight loss and cardio-protection in obese women (Nutrition Journal, 2012, PMID 23171320); Improvement in coronary heart disease risk factors during an intermittent fasting/calorie restriction regimen: relationship to adipokine modulations (Nutrition & Metabolism, 2012, PMID 23113919); Protein-pacing caloric-restriction enhances body composition similarly in obese men and women during weight loss and sustains efficacy during long-term weight maintenance (Nutrients, 2016, PMID 27483317); Intermittent fasting and protein pacing are superior to caloric restriction for weight and visceral fat loss (Obesity, 2023, DOI 10.1002/oby.23660, trial NCT04327141); Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction (Nature Communications, 2024, follow-up analysis of the 2023 trial above). The first two are the same cohort of 54 women reported twice, so that is four independent studies rather than five, and every one of them was paid for by Isagenix.